Her2 and progesterone receptor status are not predictive of response to fulvestrant treatment

Clinical Cancer Research

Volumn 13, Issue 15, 2007, Pages 4435-4439

  Bartsch, Rupert ^a   Wenzel, Catharina ^a   Altorjai, Gabriela ^a   Pluschnig, Ursula ^a   Mader, Robert M ^a   Gnant, Michael ^a   Jakesz, Raimund ^a   Rudas, Margaretha ^a   Zielinski, Christoph C ^a   Steger, Guenther G ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR BLOCKING AGENT; EXEMESTANE; FULVESTRANT; GROWTH FACTOR RECEPTOR; LETROZOLE; PROGESTERONE RECEPTOR; PROTEIN P53; TAMOXIFEN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER HORMONE THERAPY; CELL PROLIFERATION; CLINICAL TRIAL; COMPUTER PREDICTION; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HEADACHE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEPTOR DOWN REGULATION; RISK FACTOR; SIDE EFFECT; VASOMOTOR DISORDER; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DISEASE PROGRESSION; ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME;

EID: 34547657591     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-3050     Document Type: Article

References (31)

1. Howe HL, Wu X, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer 2006;107:1711-42.
2. Smigal C, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 2006;56:168-83.
3. Faneyte IF, Peterse JL, Van Tinteren H, et al. Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement. Clin Cancer Res 2004;10:4457-63.
4. Sommer S, Fuqua SA. Estrogen receptor and breast cancer. Semin Cancer Biol 2001;11:339-52.
5. Dutertre M, Smith CL. Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Ther 2000;295:431-7.
6. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
7. Paridaens R, Dirix L, Lohrisch C, et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003;14:1391-8.
8. Bajetta E, Procopie G, Ferrari L, et al. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. Cancer 2002;94:299-304.
9. Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced beast carcinoma. Cancer 2001;92:2247-58.
10. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609-18.
11. Schiff R, Massarweh SA, Shou J, et al. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004;10:331-6.
12. Sun M, Paciga JE, Feldman RI, et al. Phosphatidylinostol-3-OH kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor α (Erα) via interaction between Erα and PI3K. Cancer Res 2001;61:5985-91.
13. Stoica GE, Franke TF, Wellstein A, et al. Heregulin-β1 regulates the estrogen receptor-α expression and activity via ErbB2/PI 3-K/Akt pathway. Oncogene 2003;22:2073-87.
14. Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways is a cause for endocrine resistance in breast cancer. Clin Cancer Res 2005;11:865-70.
15. Dowsett M, Harper-Wynne C, Boeddinghaus L, et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 2001;61:8452-8.
16. Stendhal M, Ryden L, Nordenskjold B, Jonsson PE, Landberg G, Jirstrom K. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 2006;12:4614-8.
17. Arpino G, Weiss H, Lee AV, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005;97:1254-61.
18. Klijn JG, Berns EM, Bontenbal M, Foekens J. Cell biological factors associated with the response of breast cancer to systemic treatment. Cancer Treat Rev 1993;19 Suppl B:S45-63.
19. Rahko E, Blanco G, Bloigu R, Soini Y, Taivensaari-Mattila A, Yukkola A. Adverse outcome and resistance to adjuvant antiestrogen therapy in node positive postmenopausal breast cancer patients - the role of p53. Breast 2006;15:69-75.
20. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2727-57.
21. Lipton A, Ali SM, Leitzel K, et al. Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002;20:1467-2.
22. Lipton A, Ali SM, Leitzel K, et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 2003;21:1967-72.
23. Steger GG, Bartsch R, Wenzel C, et al. Fulvestrant ("Faslodex") in pre-treated patients with advanced breast cancer: a single-centre experience. Eur J Cancer 2005;41:2655-61.
24. Wakeling AE. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer 2000;7:17-28.
25. Normanno N, Di Maio M, De Maio E, et al. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 2005;12:721-47.
26. Howell A, Robertson JF, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multi-national, double-blind, randomized trial. J Clin Oncol 2004;22:1605-13.
27. Ellis MJ, Coop A, Singh B, et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 2003;63:6523-31.
28. Nicholson RI, McClelland RA, Robertson JF, Gee JM. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 1999;6:373-87.
29. Osborne CK, Schiff R, Fuqua SA, Shou J. Estrogen receptor: current understandings of its activation and modulation. Clin Cancer Res 2001;7:S4338-42.
30. Dixon JM, Jackson J, Hills M, et al. Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status. Eur J Cancer 2004;40:2742-7.
31. Lacroix M, Toillon RA, Leclercq G. p53 and breast cancer, an update. Endocr Relat Cancer 2006;13:293-5.